Joshua R. AlmondJoshua R. Almond, Ph.D.

Joshua R. Almond, Ph.D., is a Patent Agent with Knowles IP Strategies, LLC focusing on complex molecular and medicinal biology. In this capacity, he handles IP matters pertaining to signaling pathways, cellular processes, biochemistry, virology, and protein and gene-related innovation in connection with patent prosecution, litigation analysis, due diligence, freedom to operate and patentability investigations.  Prior to joining Knowles IP Strategies, Dr. Almond practiced at Cooley LLP and Nutter LLP in Boston, MA.

Dr. Almond received his Ph.D. in 2013 from Duke University School of Medicine, Department of Biochemistry, in the Laboratory of Dr. Kenneth Kreuzer, also a member of the Duke Cancer Institute.  Dr. Kreuzer’s lab carries out research in the areas of microbial pathogenesis, nucleic acid biochemistry, replication and stabilization of genes, and virology. Dr. Almond’s doctoral research examined mechanisms of replication fork processing and DSB repair in bacteriophage T4. His co-first author paper appears in Genetics.  While in graduate school, Dr. Almond received the Ruth L. Kirstein National Research Service Award (T32 Grant): NIH Viral Oncology Training Grant (2010).

In 2008, he received a B.S. in Chemistry with a concentration in Biochemistry from the University of North Carolina at Chapel Hill.  While an undergraduate, Dr. Almond carried out research in the laboratory of Dr. Matthew Redinbo where he helped characterize the enzyme β-glucuronidase after crystallization and cloned H. sapiens β-glucuronidase into an expression vector.

Dr. Almond’s publications include:

  • Nutter LLP IP Bulletin article entitled: “Changes to Patent Data Now Easier to Make in View of Enhancements to Private PAIR”; 2015.
  • Nutter LLP IP Bulletin FDA article entitled: “FDA Announces Availability of the Final Guidance for Expedited Access to Devices Intended for Unmet Medical Needs”; 2015.
  • Co-first author on the manuscript entitled: “The phage T4 MR complex, gp46/47: coordination and processing of DNA ends during double-strand break repair”; Genetics November 1, 2013 195 no. 3 739-755.

Dr. Almond is admitted to practice before the United States Patent and Trademark Office.